Phase 2 randomised trial in 76 adults with liver-dominant metastatic uveal melanoma: adding ipilimumab plus nivolumab to percutaneous hepatic perfusion raised 1-year PFS to 54.7% vs 15.8% (HR 0.34), but grade 3-4 treatment-related events rose to 82% vs 41%.
RCTn = 76
van den Hoek et al. Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial